Adam Woodrow has been President and Chief Commercial Officer since June 2019. Prior to that, he served as Chief Commercial Officer between October 2014 and June 2019.
Mr. Woodrow previously worked for Pfizer for five years in various strategic and operational commercial roles. While at Pfizer, he led the commercial development group in Pfizer's Specialty Care Business Unit, launching Xeljanz® for Rheumatoid Arthritis and Vyndaqel® for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). In addition, he led the global strategic marketing teams for a variety of products in fields ranging from rare disease to acute hospital based infections; major products included Enbrel®, Zyvox®, ReFacto® and Benefix®.
Mr. Woodrow joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President and Global Business Manager for Enbrel leading all commercial aspects of Wyeth's inflammation portfolio, co-promotion, licensing, and product development. In his 10 years at Wyeth, he held senior marketing and sales positions in the US and in his native UK. He was responsible for the successful launches of medicines in the fields of anti-infectives (Tygacil®), hemophilia (ReFacto), primary immune deficiency and women's health. Before joining Wyeth, he held sales and marketing positions with Bayer Pharmaceuticals.
Education & Accomplishments
Mr. Woodrow has a Bachelor of Science degree in Industrial Chemistry from the University of Wales College of Cardiff. During his career in the pharmaceutical industry, he worked with several non-profit societies and organizations.
What is Adam Woodrow's net worth?
The estimated net worth of Adam Woodrow is at least $1.45 million as of December 21st, 2022. Mr. Woodrow owns 651,284 shares of Paratek Pharmaceuticals stock worth more than $1,452,363 as of April 23rd. This net worth evaluation does not reflect any other assets that Mr. Woodrow may own. Additionally, Mr. Woodrow receives a salary of $763,510.00 as Insider at Paratek Pharmaceuticals. Learn More about Adam Woodrow's net worth.
How old is Adam Woodrow?
Mr. Woodrow is currently 56 years old. There are 5 older executives and no younger executives at Paratek Pharmaceuticals. The oldest executive at Paratek Pharmaceuticals is Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA, Exec. Chairman, who is 65 years old. Learn More on Adam Woodrow's age.
What is Adam Woodrow's salary?
As the Insider of Paratek Pharmaceuticals, Inc., Mr. Woodrow earns $763,510.00 per year. There are 2 executives that earn more than Mr. Woodrow. The highest earning executive at Paratek Pharmaceuticals is Dr. Evan Loh FACC, FAHA, M.D., CEO & Director, who commands a salary of $1,140,000.00 per year. Learn More on Adam Woodrow's salary.
How do I contact Adam Woodrow?
Has Adam Woodrow been buying or selling shares of Paratek Pharmaceuticals?
Adam Woodrow has not been actively trading shares of Paratek Pharmaceuticals in the last ninety days. Most recently, Adam Woodrow sold 6,750 shares of the business's stock in a transaction on Wednesday, December 21st. The shares were sold at an average price of $1.99, for a transaction totalling $13,432.50. Following the completion of the sale, the insider now directly owns 651,284 shares of the company's stock, valued at $1,296,055.16. Learn More on Adam Woodrow's trading history.
Who are Paratek Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Paratek Pharmaceuticals?
During the last year, insiders at the specialty pharmaceutical company sold shares 4 times. They sold a total of 142,346 shares worth more than $313,161.20. The most recent insider tranaction occured on August, 9th when insider Randall B Brenner sold 27,603 shares worth more than $60,726.60. Insiders at Paratek Pharmaceuticals own 8.0% of the company.
Learn More about insider trades at Paratek Pharmaceuticals. Information on this page was last updated on 8/9/2023.
